Xcout Intel
Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Subscribe to see Alzinova AB’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alzinova AB at a glance
Alzinova AB is a biotech company headquartered in Sweden. Xcout tracks 6 named people at Alzinova AB, including Julian Aleksov (Chairman of the Board).
Alzinova AB leadership
- Julian AleksovChairman of the Board
- Anders BlomBoard member
- Anders WaasBoard member
- Carol RoutledgeBoard member
- Clas MalmeströmBoard member
- Per-Göran GillbergBoard member
Alzinova AB competitors
A few of Alzinova AB's closest competitors — see the full list of competitors and alternatives →
BioArctic AB (publ) is an innovative Swedish research-based biopharma company headquartered in Stockholm, Sweden. Incorporated in 2000, it focuses on developing disease-modifying treatments for neurodegenerative diseases. The company is publicly traded and committed to corporate governance.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
EXCIVA GmbH is a privately held biotechnology company established in 2016 in Heidelberg, Germany, focused on developing clinical-stage therapeutics to improve quality of life and treat Alzheimer's disease.
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Umecrine Cognition AB is a Swedish clinical-stage pharmaceutical company based at the Karolinska Institutet Science Park in Solna, developing a novel class of drugs to treat neurological disorders of the brain.
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Get Alzinova AB's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alzinova AB in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access